Clin Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hirsch, I. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hirsch, I. B.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Diabetes 19:28, 2001
© American Diabetes Association ®, Inc., 2001

Commentary

"Seeing" Between the Lines

Irl B. Hirsch, MD

Diabetic retinopathy is the leading cause of blindness in the United States.1 Approximately 5% of people with diabetes progress to severe visual loss of 5/200 or less. It is now clear that aggressive and early treatment of hyperglycemia per se in addition to appropriate screening with dilated eye exams can prevent much of the morbidity associated with this devastating complication.

In this issue, we are reprinting the American Diabetes Association’s position statement on diabetic retinopathy (p. 29). This statement reviews the natural history of diabetic retinopathy, its screening guidelines, and the efficacy of laser therapy as treatment for this complication. In addition, the . . . [Full Text of this Article]

Footnotes

REFERENCES


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.